Skip to main content
Equibles
NTRB logo

NTRB · NutriBand Inc.

Track NTRB — free

Use NTRB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NTRB

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.50 -0.33 (-6.83%) At close · Aug 26
Going-concern doubt — cleared Jun 11, 2026

The latest filing states the doubt was alleviated.

“Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.”
View the 10-Q filed Jun 11, 2026
Market Cap
$54.95M
Shares
12.16M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.50 Open$4.74 Day$4.16–4.80 52W close$2.81–8.50 Avg vol 30d21K Short int170K · 1.4% float · 30.1d Short vol31% DataAug 2022–Aug 2026 Filing10-Q · Jun 11

Raw chart and full-history price indicators begin at the captured split on Aug 12, 2022; bars on opposite sides are not compared.

Up next

FQ3-27 quarter ends
~Oct 31, 2026 Est
Latest filing: 10-Q
filed Jun 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.64
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg +40%
above
RSI (14) 69
neutral
MACD trend Positive
52-week position 30%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +56%
trailing
6-month return +6%
trailing
YTD return −1%
this year
Relative strength −6%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.40% of float · ▲ +0.6% MoM · 30.1 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
18 holders — mid 3-yr range
Squeeze score 87
high risk · 0–100
Fundamentals
Weak
Revenue growth −5%
Y/Y
Gross margin 28%
contracting
EPS growth −161%
Y/Y
Free cash flow $-5.1M
Balance sheet $2.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −67%
past year
ATR 7.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
+40% Bullish
RSI (14)
69 Neutral
MACD trend
Positive Bullish
52-week position
30% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.40% of float · ▲ +0.6% MoM · 30.1 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $5 · 30% Range high $9
vs 200-day avg +13% vs 50-day avg +40%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NTRB
NutriBand Inc.
this stock
$54.95M -0.9% -4.8% — 1.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.79B +20.7% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.89B +5.6% +20.8% 20.2 2.3%
ARGX
Argenx SE
 $63.81B +24.5% — — 1.9%
CSLLY
Csl Ltd
 $60.07B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
18
% held
4.4%
Net QoQ
-34.2K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Rising
Shares short
170.1K
Days to cover
30.1d
Change
+1.1K sh
View
Short Volume
Short vol %
31%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
500
Value
$1.5K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
30.2%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.0M
Net income (FY)
$-8.2M
EPS diluted
$-2.58
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 22, 2026
This year
7
View

Performance

Raw-price comparisons begin at the captured split on Aug 12, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
NTRB +26.8% +56.3% +6.1% +57.9% -0.9%
SPY -0.4% +5.0% +12.4% +2.6% +12.3%
vs SPY +27.2% +51.2% -6.3% +55.3% -13.2%
Key facts CIK 1676047 CUSIP 67092M208 13F (30d) 18 filings 18 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)